Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$39.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, crucial for a biotech firm.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $39 billion, it operates in the health care sector, which is increasingly important as the demand for innovative treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1-2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by nearly 25%. The stock reacted positively the next day, increasing by 2.62%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in both profitability and revenue.

Bull Case

If the company shows a significant reduction in losses and improved revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Continued losses and failure to meet revenue expectations could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

Given the company's history of missing EPS estimates, this number will be crucial in determining market sentiment.

What are the revenue projections for the upcoming quarter?

Revenue growth is vital for investor confidence, especially in the biotech sector where continuous innovation is expected.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in operational efficiency, given recent investments in R&D.

Supporting Evidence

The options market is pricing in a larger move than historically observed, indicating potential overreaction.

Recent trends in biotech suggest a rebound in investor sentiment towards innovative therapies.

The company has a strong pipeline that could lead to future revenue growth, which may not be fully reflected in current estimates.

Key Risk

If EPS comes in below -$2.00, it could reinforce negative sentiment and lead to further stock declines.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether the company can stabilize its financial performance and show growth in revenue.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate a positive trend in operational efficiency.

Bear Confirmed If

If EPS remains above -$2.50, it would signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive turnaround narrative.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors weigh management's commentary against historical performance.

Miss

If the company misses again, the stock could decline, with historical averages suggesting a drop of about 0.14%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results for key therapies.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies to reduce losses.
4Insights into partnerships or collaborations that could enhance market position.
5Any changes in guidance for future earnings or operational targets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, crucial for a biotech firm.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1-2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by nearly 25%. The stock reacted positively the next day, increasing by 2.62%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are looking for signs of improvement in both profitability and revenue.

Bull Case

If the company shows a significant reduction in losses and improved revenue growth, it could signal a turnaround, attracting more investor interest.

Bear Case

Continued losses and failure to meet revenue expectations could lead to further declines in stock price and investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected EPS for Q2-2026?

Given the company's history of missing EPS estimates, this number will be crucial in determining market sentiment.

What are the revenue projections for the upcoming quarter?

Revenue growth is vital for investor confidence, especially in the biotech sector where continuous innovation is expected.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for a turnaround in operational efficiency, given recent investments in R&D.

Supporting Evidence

The options market is pricing in a larger move than historically observed, indicating potential overreaction.

Recent trends in biotech suggest a rebound in investor sentiment towards innovative therapies.

The company has a strong pipeline that could lead to future revenue growth, which may not be fully reflected in current estimates.

Key Risk

If EPS comes in below -$2.00, it could reinforce negative sentiment and lead to further stock declines.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether the company can stabilize its financial performance and show growth in revenue.

Bull Confirmed If

A reduction in EPS losses to below -$1.50 would indicate a positive trend in operational efficiency.

Bear Confirmed If

If EPS remains above -$2.50, it would signal ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive turnaround narrative.

In-Line / Cautious

A cautious inline report may lead to muted reactions, as investors weigh management's commentary against historical performance.

Miss

If the company misses again, the stock could decline, with historical averages suggesting a drop of about 0.14%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results for key therapies.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on cost management strategies to reduce losses.
4Insights into partnerships or collaborations that could enhance market position.
5Any changes in guidance for future earnings or operational targets.